Document is current
Any future updates will be listed below
-
Authors
van Straalen, Joeri W. https://orcid.org/0000-0002-8766-6694
Baas, Laurie
Giancane, Gabriella
Grebenkina, Lyudmila
Brunner, Jurgen
Vega-Cornejo, Gabriel
Chasnyk, Vyacheslav G.
Harel, Liora
Appenzeller, Simone
Gervais, Elisabeth
de Roock, Sytze
Wulffraat, Nico M.
Ruperto, Nicolino
Swart, Joost F.
,
-
Funding
Funding for this research was provided by:
FOREUM Foundation for Research in Rheumatology
IRCCS Istituto Giannina Gaslini
European Union (260353)
- License Information
-
More Information
Article History
Received: 30 December 2022
Accepted: 14 February 2023
First Online: 21 February 2023
Declarations
:
: Pharmachild and all participating centers obtained approval from their respective ethics committees and were conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent/assent based on existing national regulations.
: Not applicable.
: NR has received honoraria for consultancies or speaker bureaus from the following pharmaceutical companies in the past 3 years: 2 Bridge, Amgen, AstraZeneca, Aurinia, Bayer, Brystol Myers and Squibb, Celgene, inMed, Cambridge Healthcare Research, Domain Therapeutic, EMD Serono, Glaxo Smith Kline, Idorsia, Janssen, Eli Lilly, Novartis, Pfizer, Sobi, UCB. The IRCCS Istituto Giannina Gaslini (IGG), where NR works as full-time public employee has received contributions from the following industries in the last 3 years: Bristol Myers and Squibb, Eli-Lilly, F Hoffmann-La Roche, Novartis, Pfizer, Sobi. This funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment with third parties. All other authors declare no conflicts of interest.
